Dr. Kaul is a senior scientist at the Toronto General Research Institute at the University Health Network of Canada, a professor in the Department of Medicine at the University of Toronto, the director of the Division of Infectious Diseases at the University of Toronto and University Health Network, and an attending physician at the Toronto General Hospital. He is also an active member of the CanCURE research consortium.
He earned an undergraduate degree from the Faculty of Arts and Sciences in genetics and philosophy, and followed with a medical degree at the University of Toronto. He completed a World Health Organization research fellowship in HIV/STDs in Nairobi, Kenya, and a PhD at the Weatherall Institute of Molecular Medicine in the John Radcliffe Hospital in Oxford, England.
Dr. Kaul’s lab is researching the mucosal underpinning of HIV susceptibility and progression, with a focus on the mucosal immunology and microbiome of the female genital tract, foreskin, and rectum. His own research interests are about immunodeficiency and infectious diseases.
He is the principal investigator for CTNPT 022A and 022B, both of which are looking at the ability of probiotic supplementation in combination with antiretroviral therapy to reduce inflammation and harmful immune activation in people living with HIV.
